Linda Bentley, a Member in the Mintz Boston office, is quoted in a BNA’s Pharmaceutical Law & Industry Report article covering the Food and Drug Administration’s issued draft guidance intended to clarify the role of data integrity in current good manufacturing practice (CGMP) for drugs.